Загрузка...
Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model
INTRODUCTION: On the basis of reductions in diabetic kidney disease (DKD) progression and major adverse cardiovascular events observed in the landmark CREDENCE trial, canagliflozin 100 mg received an extension to its EU marketing authorisation in July 2020 to include the treatment of DKD in people w...
Сохранить в:
| Опубликовано в: : | Diabetes Ther |
|---|---|
| Главные авторы: | , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer Healthcare
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7843731/ https://ncbi.nlm.nih.gov/pubmed/33263893 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-020-00968-x |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|